1 / 41

Bio-reference laboratories (ticker: brli )

Portfolio Managers: Qi He Nan Liang Su Chen Presented April 4, 2012. Bio-reference laboratories (ticker: brli ). Agenda. introduction.

orly
Download Presentation

Bio-reference laboratories (ticker: brli )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Portfolio Managers: Qi He Nan Liang Su Chen Presented April 4, 2012 Bio-reference laboratories(ticker: brli)

  2. Agenda

  3. introduction

  4. Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. INTRODUCTION GICS Map: 35102015 – Health Care Services PEG Ratio 0.95 Source: finance. yahoo.com

  5. Macro review

  6. Source: IBIS – 62151 Diagnostic & Medical Laboratories in the US Industry Report, Feb 2012 by Sophia Snyder MACRO review Source: IBIS – 62151 Diagnostic & Medical Laboratories in the US Industry Report, Feb 2012 by Sophia Snyder

  7. MACRO review The industry revenue growth is projected to be around 2.7% due to the economy’s slow recovery. Source: IBIS – 62151 Diagnostic & Medical Laboratories in the US Industry Report, Feb 2012 by Sophia Snyder

  8. MACRO review • Key External Drivers for this industry: • Federal funding for Medicare and Medicaid • Number of people with private health insurance • Total health expenditure • Number of adults aged 50 and older • Technological changes Source: IBIS – 62151 Diagnostic & Medical Laboratories in the US Industry Report, Feb 2012 by Sophia Snyder

  9. Medicare Medicaid Heavily regulated industry MACRO review

  10. Federal and state laws applicable to billing and claims payment; • Federal and state laboratory anti- mark- up laws; • Federal and state anti- kickback laws; • Federal and state false claims laws; • Federal and state self- referral and financial inducement laws, including the federal physician anti- self- referral law, or the Stark Law; • Coverage and reimbursement levels by Medicare and other governmental payors and private insurers; • Federal and state laws governing laboratory licensing and testing, including CLIA; • Federal and state laws governing the development, use and distribution of diagnostic medical tests known as laboratory developed tests or "LDTs"; • HIPAA, along with the revisions to HIPPA as a result of the HITECH Act, and analogous state laws; • Federal, state and foreign regulation of privacy, security, electronic transactions and identity theft; • Federal, state and local laws governing the handling, transportation and disposal of medical and hazardous waste; • Occupational Safety and Health Administration rules and regulations; MACRO review Source: BRLI 2011 10-K

  11. MACRO review Source: BRLI 2011 10-K

  12. MACRO review Source: IBIS – 62151 Diagnostic & Medical Laboratories in the US Industry Report, Feb 2012 by Sophia Snyder

  13. Relevant stock market prospects

  14. Relevant stock market prospects - Competitors Source: BRLI 2011 10-K

  15. Relevant stock market prospects - Comps Source: Capital IQ

  16. RELEVANT STOCK MARKET PROSPECTS Source: BRLI 2011 10-K

  17. RELEVANT STOCK MARKET PROSPECTS

  18. RELEVANT STOCK MARKET PROSPECTS Source: finance. yahoo.com

  19. Review company & business

  20. BRLI is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. Fourth largest full-service laboratory in the United States and the largest independent regional laboratory in the Northeastern market. REVIEW COMPANY & BUSINESS Source: BRLI 2011 10-K

  21. REVIEW COMPANY & BUSINESS Source: BRLI 2011 10-K

  22. REVIEW COMPANY & BUSINESS Source: BRLI 2011 Conference Call

  23. In 2006, BRLI acquired GeneDx, a diagnostic genetic testing laboratory providing services to national and international customers. In 2008, BRLI were the first commercial laboratory in the world to offer NextGen (high speed computerized sequencing) to analyze multi- gene conditions. These innovations have significantly grown GeneDx's business. • On March 2, 2010, BRLI completed the acquisition of Lenetix Medical Screening Laboratory, Inc., a clinical testing laboratory located in Mineola, New York. The laboratory performs both clinical laboratory diagnostic testing and genetic testing. • On August 5, 2011, BRLI acquired The Genetics Center, Inc., a New York corporation engaged in the clinical laboratory business with its principal place of business in Smithtown, New York Acquisition Source: BRLI 2011 10-K

  24. REVIEW COMPANY & BUSINESS Source: BRLI 2011 10-K

  25. REVIEW COMPANY & BUSINESS Source: BRLI 2011 Conference Call

  26. REVIEW COMPANY & BUSINESS Source: BRLI 2011 Conference Call

  27. REVIEW COMPANY & BUSINESS BRLI: Esoteric Testing has Fueled Growth Source: BRLI 2011 Conference Call

  28. REVIEW COMPANY & BUSINESS Source: BRLI 2011 10-K

  29. Healthcare Reform Law: • Including programs to extend medical benefits to millions of individuals who currently lack insurance coverage, coupled with measures to cut Medicare spending for most healthcare services, including clinical laboratories. REVIEW COMPANY & BUSINESS Source: BRLI 2011 10-K

  30. REVIEW COMPANY & BUSINESS Congress has periodically considered imposing a 20 percent coinsurance on laboratory services. Under the Medicare framework, the national limitation amount for clinical laboratory services had been reduced in a number of instances over the past several years to a present level equal to 74% of the national median of laboratory charges Source: BRLI 2011 10-K

  31. FINANCIAL ANALYSIS Source: BRLI 2011 10-K

  32. FINANCIAL ANALYSIS Source: BRLI 2011 10-K

  33. FINANCIAL ANALYSIS - Payers & clients Source: BRLI 2011 10-K

  34. Financial analysis

  35. FINANCIAL ANALYSIS BRLI has demonstrated 20% CAGR over the past seventeen years with an actual increase of 26% for FY10 over FY09. Source: BRLI 2011 Conference Call

  36. FINANCIAL ANALYSIS Source: BRLI 2011 10-K

  37. FINANCIAL ANALYSIS - roe Source: BRLI 2011 10-K

  38. Financial projections

  39. Financial projections - multiples Target price: $ 19.80

  40. recommendation

  41. Recommendation Current Stock Price $23.97 DCF $23.87 Multiple $19.80 Recommendation: Watch list

More Related